Preliminary Final Report
| Stock | Fisher & Paykel Healthcare Corporation Ltd (FPH.ASX) |
|---|---|
| Release Time | 28 May 2025, 7:31 a.m. |
| Price Sensitive | Yes |
Record full-year revenue result for Fisher & Paykel Healthcare
- 16% growth in operating revenue to $2.02 billion
- 43% growth in underlying net profit after tax to $377.2 million
- 18% growth in Hospital operating revenue to $1.28 billion
Fisher & Paykel Healthcare Corporation Limited today announced its results for the full year ended 31 March 2025. Total operating revenue was a record $2.02 billion, an increase of 16% from the prior financial year, or 14% in constant currency. This was driven by broad-based growth in hospital consumables and double-digit growth in masks for treating obstructive sleep apnea. Net profit after tax for the financial year was $377.2 million, a 43% increase over the 2024 financial year, or 30% in constant currency. For the Hospital product group, revenue for the full year was $1.28 billion, up 18% from the previous financial year, or 16% in constant currency. Sales of new applications consumables were up 20% over the prior financial year, or 18% in constant currency. For the Homecare product group, revenue for the full year was $739.9 million, up 13% over the previous financial year, or 11% in constant currency. OSA masks revenue was up 14% for the full year, or 11% in constant currency. The company remains committed to returning to its long-term gross margin target of 65%. For the 2025 financial year, gross margin was 62.9%, an underlying performance increase of 181 basis points, or 129 basis points in constant currency.
At 30 April exchange rates, the company expects full year operating revenue to be in the range of approximately $2.15 billion to $2.25 billion, and net profit after tax to be in the range of approximately $390 million to $440 million. This outlook anticipates an overall improvement in gross margin for the year and includes an estimated 50-basis point impact of US tariffs on hospital products sourced from New Zealand.
Looking ahead, the company will continue to apply the fundamental principles that have guided it for decades. It has a strong new product pipeline and is confident that it will continue to introduce innovative products and therapies that enhance patient care and improve health outcomes worldwide.